As of today (2024-04-19), Amgen's share price is $268.93.
Amgen's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $13.69. Hence, Amgen's Price-to-Free-Cash-Flow Ratio for today is 19.64.
The historical rank and industry rank for Amgen's Price-to-Free-Cash-Flow or its related term are showing as below:
AMGN'
s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 11.06 Med: 14.61 Max: 23.61
Current: 19.64
During the past 13 years, Amgen's highest Price-to-Free-Cash-Flow Ratio was 23.61. The lowest was 11.06. And the median was 14.61.
AMGN's Price-to-Free-Cash-Flow is ranked better than 53.83% of 496
companies
in the Drug Manufacturers industry
Industry Median: 21.17
vs AMGN: 19.64
During the past 12 months, the average Free Cash Flow per Share Growth Rate of Amgen was -15.80% per year.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was -6.60% per year.
During the past 5 years, the average Free Cash Flow per Share Growth Rate was -1.30% per year.
During the past 10 years, the average Free Cash Flow per Share Growth Rate was 5.70% per year.
During the past 13 years, Amgen's highest 3-Year average Free Cash Flow per Share Growth Rate was 104.00% per year. The lowest was -6.60% per year. And the median was 14.20% per year.
Amgen Price-to-Free-Cash-Flow Historical Data
The historical data trend for Amgen's Price-to-Free-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Amgen Annual Data
Trend
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
Price-to-Free-Cash-Flow
17.21
13.72
15.38
16.17
21.06
Amgen Quarterly Data
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
Price-to-Free-Cash-Flow
16.17
17.26
12.32
15.41
21.06
Competitive Comparison
For the Drug Manufacturers - General subindustry, Amgen's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amgen Price-to-Free-Cash-Flow Distribution
For the Drug Manufacturers industry and Healthcare sector, Amgen's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Amgen's Price-to-Free-Cash-Flow falls into.
Amgen Price-to-Free-Cash-Flow Calculation
Amgen's Price-to-Free-Cash-Flow ratio for today is calculated as
Amgen's Share Price of today is $268.93.
Amgen's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $13.69.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
Amgen Price-to-Free-Cash-Flow Related Terms
Thank you for viewing the detailed overview of Amgen's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AMGN has been successfully added to your 